Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + Ribavirin +/- PEG in Chronic HCV
NCT02021643Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of sofosbuvir in hepatitis C (HCV) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event. Started Dec 2013; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02021643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021643.